Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer is pleased to announce that it has been granted a further extension to its option to licence the commercial use of Ichor Medical Systems’ (“Ichor’s”) proprietary TriGrid® electroporation delivery system with SCIB1, Scancell’s ImmunoBody® vaccine for the treatment of melanoma. In exchange, Scancell has granted a partial waiver over the lock-up which prohibited the sale, during the two years following their issue, of ordinary shares in the Company (“Ordinary Shares”) issued pursuant to exercise of the Tranche 2 share options (over 3,184,620 Ordinary Shares), issued as part payment for the licence option, as originally announced 16 July 2009 and extended in July 2014. Subject to exercise of the Tranche 2 share options, Ichor will remain under an orderly market agreement requiring any sale of such Ordinary Shares during that two year period to be effected through Scancell’s brokers.

Under the terms of the agreed extension, Scancell’s licence option, which had been due to expire on 13 July 2016, has been extended until 13 July 2018.

Richard Goodfellow, CEO of Scancell, said:

“Ichor’s proprietary TriGrid® electroporation delivery system remains central to our studies on SCIB1 and in particular, to our upcoming US clinical study of SCIB1 in combination with a checkpoint inhibitor, expected to commence in 2017. We are delighted to have extended the licence option agreement to commercialise their technology on the terms as set out above and we appreciate Ichor’s continued support of our SCIB1 programme as we continue its clinical development as a potential treatment for patients with melanoma.”

Robert Bernard, President & CEO of Ichor, added:

“Scancell has continued to generate outstanding survival data using our TriGrid® electroporation delivery system in conjunction with their lead ImmunoBody® vaccine, SCIB1. We believe that SCIB1 has the potential to be a significant new treatment option for patients with melanoma, and we look forward to continuing to work with Scancell on this exciting product.”

For Further Information:

Dr John Chiplin, Executive Chairman Dr Richard Goodfellow, CEO	Scancell Holdings Plc	+1 858 900 2646 +44 (0) 20 3727 1000
Freddy Crossley (Corporate Finance) Tom Salvesen (Corporate Broking)	Panmure Gordon & Co	+44 (0) 20 7886 2500 +44 (0) 20 7886 2500
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

About Ichor and the TriGrid® Delivery System

Ichor is dedicated to the clinical application and commercialization of electroporation technology for the delivery of DNA drugs and vaccines to treat and prevent debilitating or life threatening diseases. They are applying their proprietary TriGri® Delivery System to enable delivery of DNA drugs to address unmet medical needs in areas including therapeutic cancer vaccines, therapeutic proteins and vaccines for serious infectious disease.

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Scancell to present update at the Oxford Technology VCT AGM and Proactive Investors One2One Forum

Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, today provides an update from the SCIB1 Phase 1/2 clinical trial in malignant melanoma, the lead programme from the Company’s ImmunoBody® platform and will be presenting at the Oxford Technology VCT AGM and Proactive Investors One2One Forum later this week.

Dr Richard Goodfellow, CEO of Scancell, said: “SCIB1 continues to deliver compelling survival data in patients with resected Stage III/IV melanoma. It is particularly interesting to note that there has only been one new case of disease progression since November 2013 in the resected patients receiving 4mg doses of SCIB1, which gives us hope that SCIB1 might offer curative potential in this currently untreated patient group.”

Dr Keith Flaherty, Director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School, commented: “The SCIB1 overall survival and progression free survival data generated to date go well beyond established norms for this group of melanoma patients. We have a lot of enthusiasm for validating these results in subsequent trials.”

SCIB1 Survival Update

As of 27 June 2016, SCIB1 continues to deliver strong survival data:

• Currently 19 of the 20 patients with resected tumours at study entry remain alive
• One patient who first experienced disease progression in September 2013 died in April 2016, despite additional treatment with checkpoint inhibitors and radiation therapy
• Of the 16 patients who received 2-4mg doses of SCIB1 Median observation time since entry is 46 months and 52 months since first diagnosis of metastatic disease
• Only five patients have progressed and one has died
• Only one new incidence of disease progression has been seen since November 2013
• Of the four patients who received 8mg doses of SCIB1 (recruited after lower dose cohorts)
• Median observation time since entry is 16 months and 21 months since first diagnosis of metastatic disease
• None have progressed and none have died
• As announced on 17 June 2016, treatment for the eight patients in the long-term continued dosing phase has been suspended due to the clinical trial supplies no longer being within the original specification
• New SCIB1 material being manufactured to support a new study of SCIB1 in combination with a checkpoint inhibitor will also be made available to these continuation patients (subject to regulatory approval)
• New SCIB1 material will be ready for use in approximately 9-12 months
• Plans for the US clinical study of SCIB1 in combination with a checkpoint inhibitor remain on track
• The final Clinical Study Report, which will be issued later this year, will provide safety, immunology and clinical data from all patients up to 29 October 2015 (the date of the last patient’s dose in the main study) to support our US regulatory submission

Investor Events

Proactive One2One Forum, 7 July 2016 – Dr Richard Goodfellow
The event will commence at 6.00pm at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair. Attendance is free. Proactive Investors One2One Forums have rapidly gained global recognition for companies to present
to an audience of astute high net worth investors, fund managers, private client brokers and analysts. See Proactive Investors website for more details: http://www.proactiveinvestors.co.uk/register/event_details/65

Oxford Technology VCT AGM, 8 July 2016 – Dr John Chiplin

Scancell will be speaking as part of the portfolio review at the Oxford Technology VCT AGM which commences at 11am at the Magdalen Centre, Oxford Science Park, Oxford OX4 4GA. The Company will provide a corporate presentation and will provide an update on its immunotherapy platform technologies:

• ImmunoBody® - Best-in-class DNA vaccine technology for use in combination with checkpoint inhibitors or as monotherapy for patients with resected disease
• Moditope® - Novel immunotherapy that destroys tumours and extends survival without the need for checkpoint inhibition

For Further Information:

Dr John Chiplin, Executive Chairman Dr Richard Goodfellow, CEO	Scancell Holdings Plc	+1 858 900 2646 + 44 (0) 20 3727 1000
Freddy Crossley (Corporate Finance) Maisie Atkinson (Sales)	Panmure Gordon & Co	+44 (0) 20 7886 2500 +44 (0) 20 7886 2905
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

About Scancell
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour
load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer
survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could
play a major role in the development of safe and effective cancer immunotherapies in the future.

Research undertaken by scientists at Nottingham Trent University and the University of Portsmouth

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that researchers at Nottingham Trent University and the University of Portsmouth have initiated a new preclinical study aimed at developing a vaccine for the treatment of glioblastoma multiforme (GBM) by utilising Scancell’s ImmunoBody® technology platform.

GBM is the most common and aggressive form of glioma and carries a very poor prognosis. Around 5,000 people are diagnosed with a primary malignant brain tumour in the UK each year and GBM accounts for just over half of them. Treatments are limited and even with intensive chemotherapy patients have an average survival time of just 14 months.

Due to the highly aggressive nature of GBM and the lack of successful curative treatments to date, there is an urgent need for novel therapeutic approaches such as immunotherapy.

By using Scancell’s ImmunoBody® technology platform, scientists at Nottingham Trent University and the University of Portsmouth are aiming to develop a vaccine that stimulates protective immune responses against tumour molecules such as ‘HAGE’ and ‘TRP2’, which are proteins that are expressed in the cancer cells of GBM patients.

The vaccine treatment will be assessed for its ability to generate strong anti-GBM tumour immunity, as well as the ability to reduce and eradicate established tumours.

The researchers will also determine whether the vaccine stimulates HAGE and/or TRP2-specific immune cells in the blood of GBM patients that are capable of recognising the GBM tumours. This will demonstrate the ability of a patient’s immune system to identify and kill the cancer cells, providing insight into the effectiveness of the treatment.

The £95,000 study is being funded by the Headcase Cancer Trust, the only UK charity which dedicates its funding solely to research which aims to find a cure for GBM brain tumours.

Professor Lindy Durrant, Chief Scientific Officer of Scancell commented:

“We are keen to collaborate on this exciting project to add HAGE to our TRP-2/gp100 vaccine to target GBM. It is an aggressive disease and we believe the high avidity T cells generated by ImmunoBody® will be needed to control its growth.”

Dr Stephanie McArdle, a scientist in the John van Geest Cancer Research Centre at Nottingham Trent University, said:

“Vaccines can be extremely powerful when correctly formulated, so we are very hopeful that combining HAGE and TRP-2/gp100 with Scancell’s ImmunoBody® technology will lead to better disease outcomes.”

-ENDS-

For Further Information:

Dr John Chiplin, Executive Chairman	Scancell Holdings Plc	+1 858 900 2646
Dr Richard Goodfellow, CEO		+44 (0) 20 3727 1000
Dave Rogers (Senior Press Officer)	Nottingham Trent University	+44 (0) 115 848 8782
Helen Breese (Senior Press Officer)		+44 (0) 115 848 8751
Freddy Crossley (Corporate Finance)	Panmure Gordon & Co	+44 (0) 20 7886 2500
Maisie Atkinson (Sales)		+44 (0) 20 7886 2905
Mo Noonan/Simon Conway	FTI Consulting	+44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

About John van Geest Cancer Research Centre, Nottingham Trent University

Nottingham Trent University’s John van Geest Cancer Research Centre is a unique purpose-built scientific facility. Its aim is to save lives and speed recovery by improving the early diagnosis and treatment of cancer.

The centre focuses on two key approaches to the treatment of patients with cancer:

Improving the diagnosis and management of breast and prostate cancers

Developing effective vaccines and immunotherapies that will significantly improve the survival rates and quality of life for cancer sufferers

Visit the John van Geest Cancer Research Centre website to find out more about its work, or to make a donation towards its vital scientific research.

Scancell Holdings Plc, (AIM:SCLP), today announces the opening of new offices in San Diego to support the Company’s ambitious US growth plans together with plans to establish a new base in the Oxford area for its UK corporate and development activities.

In addition, the following changes have been made to the structure of Scancell’s executive management team to optimally align management expertise with the strategic direction outlined in the £6.2m ($9m) fundraising completed in April.

Dr John Chiplin, who is based in the US and is currently Scancell’s Non-Executive Chairman, will assume the role of Executive Chairman. John will be directly involved in raising the corporate profile of the Company in the US. Recent US transaction experience, as a director/CEO, includes Benitec Biopharma (US IPO), Medistem (acquired by Intrexon), Arana (acquired by Cephalon) and Domantis (acquired by GSK). Prior to Scancell John was CEO of Polynoma, a Phase III cancer vaccine company, based in San Diego.

Dr Richard Goodfellow, currently Joint CEO, will become Chief Executive Officer and Professor Lindy Durrant, currently Joint CEO, will become Chief Scientific Officer, allowing her to focus fully on the innovative drug discovery that underpins Scancell’s novel technology platforms.

Dr Sally Adams will remain as Development Director.

Dr John Chiplin, Executive Chairman of Scancell commented: “The Board believes that these changes align management with the strategic direction outlined at the time of our recent £6m fundraising and optimally leverage expertise with the needs of the Company. Scancell’s next generation cancer vaccine platforms, ImmunoBody® and Moditope®, are delivering outstanding results and I am convinced that Scancell will secure wider recognition for its innovative technologies and products in both the United States and Europe over the coming months.”

-ENDS-

Dr John Chiplin, Executive Chairman	Scancell Holdings Plc	+ 44 (0) 20 3727 1000
Dr Richard Goodfellow, CEO
Rob Naylor (Corporate Finance)	Panmure Gordon & Co	+44 (0) 20 7886 2714
Maisie Atkinson (Sales)		+44 (0) 20 7886 2905
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

On 9 March 2016 the Board of Scancell announced details of a Placing in which it had conditionally raised gross proceeds of £3.4 million by means of a Placing of 20,000,000 Placing shares at 17 pence per share.

In addition, the Company announced that it was providing Qualifying Shareholders with an opportunity to subscribe, at 17 pence per share, for 22,495,068 new Ordinary Shares to raise gross proceeds of up to approximately £3.8 million by way of the Open Offer.

The Company has received subscriptions in respect of 16,048,593 new Ordinary Shares, representing 71.3 per cent. of the new Ordinary Shares available under the Open Offer. All applications made pursuant to the Open Offer including the Excess Shares applied for under the Excess Application Facility have been met in full. The Company has therefore raised gross proceeds of approximately £2.7 million through the Open Offer.

John Chiplin, Non-Executive Chairman of Scancell, said: "We are delighted that, through our Placing and Open Offer, the Company has successfully raised £6.1 million. We would like to thank our existing shareholders for their continued support, as well as welcoming new investors, at this important time in the Company’s evolution. As a result of this fundraising we are now able to accelerate the development of both our ImmunoBody® and Moditope® platform technologies. We will use the money raised to prepare for our SCIB1 ImmunoBody® / checkpoint inhibitor combination study in melanoma, including applying for a US IND later this year, enabling the study to begin in 2017 and also to take our first Moditope® product, Modi-1, into the clinic next year. We will continue to strengthen our Board and management team and increase our focus on the US with the goal of becoming one of the leading cancer immunotherapy companies.”

For further information please contact:

Scancell Holdings Plc Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO	+44 (0) 20 3727 1000
Panmure Gordon (Nominated Adviser and placing agent) Robert Naylor/Paul Fincham, Corporate Finance Maisie Atkinson, Sales	+44 (0) 20 7886 2500
Lesmoir-Gordon, Boyle & Co. Limited (Sub placing agent) Angus Grierson	+44 (0) 20 7518 9892
FTI Consulting Mo Noonan Simon Conway	+44 (0) 20 3727 1000

 

Application will be made to the London Stock Exchange for the admission to trading on AIM of the 36,048,593 new Ordinary Shares to be issued under the Placing and Open Offer. It is expected that Admission will occur and that dealings will commence at 08:00 a.m. on 5 April 2015. The total number of Ordinary Shares following Admission will be 260,999,276 with each share carrying the right to one vote. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in Scancell under the FCA's Disclosure and Transparency Rules.

This announcement should be read in conjunction with the full text of the Circular posted to Shareholders on 11 March 2016, copies of which are available on the Company's website at www.scancell.co.uk. Capitalised terms not otherwise defined in this announcement have the meanings given in the Circular.

Scancell’s SCIB1 ImmunoBody® cancer vaccine being presented at the World Vaccine Congress Scancell Holdings plc, (‘Scancell’ or the 'Company’) the developer of novel immunotherapies for the treatment of cancer, announces that Dr Peter Brown, Clinical and Scientific Consultant, Immunotherapeutics, at Scancell, will be presenting an update on the Company’s SCIB1 ImmunoBody® cancer vaccine at the World Vaccine Congress US 2016, 29-31 March 2016, in Washington D.C., US.

The presentation entitled: “SCIB1 ImmunoBody® stimulates a potent T cell response that eradicates tumours and prevents recurrence” will be presented on Wednesday 30 March 2016 at 11:40am EDT.

Scancell’s first ImmunoBody®, SCIB1, is currently being evaluated in a Phase 1/2 clinical trial in patients with Stage III/IV melanoma. The latest data suggests that SCIB1 may have the potential to significantly extend survival times in patients, especially in those with resected disease. The Company is in the process of preparing a final clinical study report. A Phase 2 checkpoint inhibitor combination study of SCIB1 in melanoma is due to commence in 2017.

Richard Goodfellow, Joint CEO of Scancell, commented:

“We are delighted to be presenting an update on SCIB1 at the World Vaccine Congress, alongside some of the most distinguished companies in the immunotherapy field. Funds from the recently announced placing
and the pending open offer will be used to further progress our ImmunoBody® and Moditope® platforms, including helping to fund our expanded SCIB1 clinical trial programme, which will be led by a team of leading US specialists.”

For Further Information:

Dr Richard Goodfellow, Joint CEO Professor Lindy Durrant, Joint CEO	Scancell Holdings Plc	+ 44 (0) 20 3727 1000
Robert Naylor (Corporate Finance) Maisie Atkinson (Sales)	Panmure Gordon & Co	+44 (0) 20 7886 2714 +44 (0) 20 7886 2905
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

 

SCIB1 mechanism of action

SCIB1 is a DNA ImmunoBody® immunotherapy encoding a human IgG1 antibody, with three epitopes from gp100 and one from TRP-2 engineered into its CDR regions. This immuno-stimulatory antibody targets dendritic cells in vivo via the high affinity Fc receptor, CD64, and stimulates high avidity T cells. Extensive research studies suggest SCIB1 ImmunoBody® has a dual mechanism of action that combines crosspresentation
with direct-presentation. This results in amplification of the immune response to induce high frequency, high avidity T cells which translates into a potent anti-tumour response.

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer
survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could
play a major role in the development of safe and effective cancer immunotherapies in the future.

Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, announces that the Company will be presenting at the Biotech Capital Conference on
Thursday 3 March 2016.

Dr Richard Goodfellow will present an update on the Company’s immunotherapy platform technologies:

• ImmunoBody® - Potent DNA vaccine technology for use in combination with checkpoint inhibitors or as monotherapy for patients with resected disease
• Moditope® - Novel immunotherapy that destroys tumours and extends survival without the need for checkpoint inhibition

The event will commence at 9.00am at 52 Chiswell Street, London, EC1Y 4SD. Attendance is free, with registration via www.biotech-capital.com/conferences.

The Biotech Capital Conferences are a new institutionally focused platform for listed Biotech companies to reach out to a very active pool of investors. Participants include Biotech investors, investment managers,
private client brokers and analysts who want exclusive access to the management of some of the market’s most interesting, high growth companies.

A recording of the presentation will be available on the Company’s website following the event.

For Further Information:

Dr Richard Goodfellow, Joint CEO	Scancell Holdings Plc	+ 44 (0) 20 3727 1000
Professor Lindy Durrant, Joint CEO
Charles Breese	Larpent Newton	+44 (0) 12 8070 3482
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

 

 

 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer
survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could
play a major role in the development of safe and effective cancer immunotherapies in the future.

Scancell focuses on the US in a transformational year

Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, announces its interim results for the six months ended 31 October 2015.

Highlights:

• Completion of the main study period of the Phase 1/2 clinical trial of SCIB1 ImmunoBody® in patients with Stage III/IV melanoma with continued strong survival data
  • All 20 patients with resected disease remain alive
  • Median observation time in 16 patients who received 2-4mg is now 42 months since study entry and 11 remain disease free
  • Median observation time in four resected patients who received 8mg is 10 months and all remain disease free
  • All nine patients currently on long-term treatment remain disease free up to 39 months from start of SCIB1 treatment
  • Final clinical study report expected in H1 2016
• Continued good progress in development of lead product, Modi-1, from Moditope® platform
  • Improvement in peptide components suggest Modi-1 will be effective in up to 95% of patients with triple negative breast and ovarian cancers
  • Clinical studies anticipated to commence in 2017
  • Important paper outlining the scientific basis for the Moditope® platform published in revered cancer journal, Cancer Research
• Loss for the six month period of £1.17 million (2014: loss: £1.34 million)
• Group cash balance at 31 October 2015 was £1.81 million (30 April 2015: £3.06 million)

Post Period Highlights

• Prestigious US scientific team to lead Phase 2 checkpoint inhibitor combination study with SCIB1, expected to commence in 2017
• Results from first pilot study indicate ImmunTraCkeR® has the potential to be used as a companion diagnostic to predict early response to SCIB1. Further studies planned
• John Chiplin appointed Chairman, succeeding David Evans who has stepped down from the role 

Richard Goodfellow, Joint CEO of Scancell, said: “Scancell is in the midst of an exciting transformation. Our focus on the US has resulted in the appointment of Dr Keith Flaherty, one of the world leaders in melanoma
clinical research as Principal Investigator for our planned SCIB1/checkpoint inhibitor combination study. The SCIB1 survival data, especially in patients with resected disease is extremely encouraging. All 20 patients with resected Stage III/IV disease remain alive and only 5 have any evidence of disease progression. The strength of the Moditope® platform has been endorsed by the publication of data supporting its scientific basis in Cancer Research, one of the most influential cancer journals in the world. We have strengthened the clinical development team with the appointment of Dr Peter Brown, former Global Head of Oncology at Teva Pharmaceuticals and recently appointed Dr John Chiplin as Chairman, both of whom are US based. We are attracting renewed interest from both investors and pharmaceutical companies on both sides of the Atlantic. Cancer immunotherapy is becoming one of the most important clinical advances of our generation and I have never been more optimistic about the company, its research and the potential for future growth”.

A full copy of the announcement can be found on the Scancell website: www.scancell.co.uk

For Further Information:

Dr Richard Goodfellow, Joint CEO	Scancell Holdings Plc	+ 44 (0) 20 3727 1000
Professor Lindy Durrant, Joint CEO
Robert Naylor/Maisie Atkinson	Panmure Gordon	+44 (0) 20 7886 2500
Mo Noonan/Simon Conway	FTI Consulting	+ 44 (0) 20 3727 1000

 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and
Moditope® technology platforms.
Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells. 

Pre-clinical data on a combination of SCIB1 and checkpoint inhibition (blockade of the PD-1 immune checkpoint pathway) has shown enhanced tumour destruction and significantly longer survival times than
when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could
play a major role in the development of safe and effective cancer immunotherapies in the future.

CHAIRMAN’S STATEMENT

I am pleased to report the Company’s interim results for the period ended 31 October 2015. During the period the Company has continued to make good progress across all fronts.

• The latest survival and safety data from the Phase 1/2 clinical trial continues to suggest that SCIB1has the potential to become both the first stand-alone adjuvant treatment for early stage metastatic melanoma and an attractive partner with checkpoint inhibitors for later stage disease.
• Results from a pilot study with ImmunID illustrate ImmunTraCkeR®’s potential to be used as a companion diagnostic to predict early clinical response to SCIB1, both during further clinical trials and during subsequent routine clinical use.
• Scancell is to work with leading US melanoma specialists to conduct a Phase 2 checkpoint inhibitor combination study with SCIB1. This pivotal initiative which aims to demonstrate an increase in the response rates to checkpoint inhibitor therapy without additional toxicity is expected to commence in early 2017.
• The Company’s second immunotherapy platform received a significant boost following the publication of a paper in Cancer Research underpinning the scientific basis for the Moditope® platform.
• Progress has been made in the pre-clinical development of Modi-1, the lead pipeline candidate from the Moditope® platform significantly increasing the number of patients with triple negative breast and ovarian cancer eligible for treatment.

Financial

Profit and Loss Account

The Group made an overall operating loss for the six month period to 31 October 2015 of £1.37 million (2014: loss of £1.56 million). The reduced loss reflects a fall in research and development expenditure in the period as the SCIB1 clinical trial reaches completion and includes a reduction in administrative expenditure.

Overall the loss for the six month period was £1.17 million (2014: loss £1.34).

Balance Sheet

The cash at bank at 31 October 2015 was £1,813,718 (30 April 2015: £3,059,001) and net assets amounted to £5,606,941 (30 April 2015: £6,754,002).

ImmunoBody® platform

Scancell’s ImmunoBody® immunotherapy platform uses the body’s immune system to identify, attack and destroy tumours. This is achieved by enhancing the uptake and presentation of cancer antigens to harness
high avidity T cell responses. Each ImmunoBody® vaccine can be designed to target a particular cancer in a highly specific manner, offering the potential for enhanced efficacy and safety compared with more
conventional approaches. The platform has been validated both in animals and in the clinic with the Company’s first cancer vaccine, SCIB1, and many opportunities also exist for the development of a pipeline of ImmunoBody® vaccines, both for cancer and chronic infectious diseases.

SCIB1 melanoma vaccine
In July this year the Company announced that it has closed patient recruitment for its SCIB1 ImmunoBody® Phase 1/2 clinical trial in patients with Stage III/IV melanoma.

The Phase 1/2 clinical trial, conducted across six UK centres, is an open label, non-randomised study to determine the safety and tolerability of SCIB1 administered intramuscularly using an electroporation device (TriGrid Delivery System, manufactured by Ichor Medical Systems, USA). Part 1 was a dose-escalation to determine the dose for Part 2. While the primary objective of the study was to assess safety and tolerability, the study is also assessing immune response, anti-tumour activity and the ability of SCIB1 to delay or prevent disease recurrence in patients with resected disease.

In line with previously reported results, SCIB1 continues to be a safe and well tolerated treatment with no withdrawals from the study due to drug-related adverse events. All 20 patients with resected disease remain alive. The median observation time in the 16 patients with resected disease who received 2-4 mg doses of SCIB1 is now 42 months since study entry and 11 are still disease free. The median observation time for the resected patients on the 8mg dose who were recruited to the study later is 10 months and all are still disease free to date. Patients on long-term continuation treatment will continue to be dosed for up to five years from the end of the main study period. Nine patients are currently on long-term treatment (up to 11 treatments given) and all remain disease free for periods of up to 39 months from the start of treatment.

The main study closed on 29 October 2015. The Company is in the process of analysing the data and preparing a final clinical study report which is expected to be completed during the first half of 2016.

The enhanced survival and safety in our SCIB1 study combined with the novel mechanism of action which delivers high T cell avidity, has re-ignited the interest of pharmaceutical companies, especially in combination with checkpoint inhibitors.

SCIB2 vaccine
Our second ImmunoBody® vaccine, SCIB2 has been designed to be effective in over 90% of patients that over express the cancer antigen NY-ESO-1, including those with lung and other epithelial cancers.

US Clinical Study
The Company has announced the formation of a core US investigator team to lead a checkpoint inhibitor combination study with Scancell’s lead cancer vaccine, SCIB1. The team will be led by Principal Investigator Dr Keith Flaherty, Director of the Termeer Center for Targeted Therapy at Massachusetts General Hospital and Associate Professor at Harvard Medical School and will be supported, amongst others yet to be announced, by:

• Dr Paul Chapman (Memorial Sloan Kettering)
• Dr Jennifer Wargo and Dr Michael Davies (MD Anderson)
• Dr Rene Gonzalez (University of Colorado)

The clinical study will assess the impact of adding SCIB1 to checkpoint inhibitors in patients with late stage melanoma. The aim will be to improve the objective response rates of anti-PD-1 (“checkpoint inhibitor”) monotherapy without adding additional toxicity. It is expected that the study will enrol approximately 80 Stage III/IV metastatic melanoma patients and commence in early 2017, with completion approximately 18 months later. We are delighted to have secured the help and support of such a prestigious group of US specialists to undertake this important study.

ImmunID Collaboration
The Company is continuing to work with ImmunID on a research project aimed at predicting which patients will respond best to SCIB1 treatment. This collaboration is providing further insight into T cell diversity in patients treated with our SCIB1 vaccine and their response to the treatment over time. Results from the first pilot study with ImmunTraCkeR® have indicated its potential to be used as a companion diagnostic to predict early clinical response to SCIB1 both during further clinical trials with SCIB1 and during routine clinical use; further studies are planned.

Moditope® platform

Modi-1
Scancell’s Moditope® immunotherapy platform is based on exploiting the normal immune response to stressed cells, which is largely mediated by CD4+ T cells, and harnessing this mechanism to eradicate cancer cells. Scancell’s first target for Moditope® is vimentin – a major cytoskeletal protein found in mesenchymal cells. Many epithelial tumours switch from expression of cytokeratin to vimentin during metastasis in a process known as epithelial mesenchymal transition (EMT); this change in phenotype enables the cell to become mobile and metastasize to new locations in the body.

The pre-clinical development of Modi-1, the lead candidate from our Moditiope® platform technology is continuing to progress and the peptide components have now been modified to include an additional enolase peptide. This improvement has meant that the product is expected to be effective in up to 95% of patients with triple negative breast and ovarian cancers. The Company expects to start clinical trials with Modi-1 in 2017.

The Company was also delighted to announce in January the publication of a paper in Cancer Research underpinning the scientific basis for the Moditope® platform. Cancer Research is one of the most highly regarded and widely read cancer journals and publication in this prestigious journal is a tribute to Scancell’s scientific team under the leadership of Prof Lindy Durrant.

Board

Scancell has strengthened its commercial and clinical development expertise with the appointment of Dr Peter Brown as an advisor to the Company and myself to the Board, initially as a senior Non-Executive Director and now as Chairman. David Evans has stepped down as Chairman and the Board would like to thank him for his exemplary leadership and sage advice during his tenure.

Peter is a highly experienced pre-clinical and clinical development consultant to the pharmaceutical industry and his expertise in designing and managing international late stage oncology clinical trials in both small and large pharmaceutical companies will be of enormous help as the Company continues to grow.

Outlook
The latest data on SCIB1, both in terms of the unprecedented survival of Stage III/IV melanoma patients with resected disease, combined with anti-tumour responses in late stage patients and compelling animal data showing the potential value of a SCIB1/checkpoint inhibitor combination, has set the stage for an expanded clinical trial programme with a prestigious group of US specialists.

Progress has also continued to be made with the Moditope® platform and it is anticipated that the first product, Modi-1, will be moving into the clinic in 2017. Publication of the scientific data supporting the Moditope® platform in Cancer Research is also a key milestone and a tribute to the strength of the Company’s research team.

These developments have reignited interest in the Company from all of its stakeholders, including the pharmaceutical industry and potential new investors, especially in the US.

The Board believes that investment in further focused clinical studies on both SCIB1 and Moditope® could add significant value to the Company and is exploring with its advisers a number of funding options to ensure
that the Company has the resources to progress these programmes further.

As part of this process, the Board and management will be further strengthened to prepare the Company for its future as a later stage development company.

I have become Chairman as the Company is poised for an exciting future and I am committed to strengthening our presence in the US and to building the Company into one of the leaders in immunooncology.

John Chiplin
Chairman

Scancell Holdings plc
Consolidated Profit or Loss and Other Comprehensive Income Statement
for the six months to 31 October 2015
 

	Unaudited Six months 31/10/2015 £	Unaudited Six months 31/10/2014 £	Unaudited Six months 30/04/2015 £
Continuing operations
Development expenses	(938,211)	(1,072,984)	(1,998,366)
Administrative expenses	(429,563)	(487,829)	(961,629)
OPERATING LOSS	(1,367,774)	(1,560,813)	(2,959,995)
Interest receivable and similar income	12,011	70,898	131,513
LOSS BEFORE TAXATION	(1,355,763)	(1,489,915)	(2,828,482)
Tax on loss on ordinary activities	180,800	150,000	413,852
LOSS FOR THE PERIOD	(1,174,963)	(1,339,915)	(2,414,630)
Attributable to: Equity holders of the parent company	(1,174,963)	(1,339,915)	(2,414,630)
EARNINGS PER ORDINARY SHARE (PENCE) Note2
Basic	(0.52)	(0.60)	(1.07)
Diluted	(0.52)	(0.60)	(1.07)

 

Scancell Holdings plc
Consolidated Statement of Changes in Equity for the six month period to 31 October 2015

 

 

	Share capital £ Unaudited	Share premium account £ Unaudited	Share option reserve £ Unaudited	Retained earnings £ Unaudited	Total Equity £ Unaudited
At May 2015	224,951	16,036,276	613,726	(10,120,951)	6,754,002
(Loss) for the period				(1,174,963)	(1,174,963)
Share option costs			27,902		27,902
At 31 October 2015	224,951	16,036,276	641,628	(11,295,914)	5,606,941
At 1 May 2014	224,951	16,036,276	522,358	(7,706,321)	9,077,264
(Loss) for the period				(1,339,915)	(1,339,915)
Share option costs			46,867		46,867
At 31 October 2014	224,951	16,036,276	569,225	(9,046,236)	7,784,216
	Audited	Audited	Audited	Audited	Audited
At 1 May 2014	224,951	16,036,376	522,358	(7,706,321)	9,077,264
(Loss) for the year				(2,414,630)	(2,414,630)
Share option costs			91,368		91,368
At 30 April 2015	224,951	16,036.276	613,726	(10,120,951)	6,754,002

 

Scancell Holdings plc

Consolidated Statement of Financial Position as at 31 October 2015

	Unaudited 31/10/2015 £	Unaudited 31/10/2014 £	Unaudited 30/04/2015 £
ASSETS
Non-current assets
Plant and equipment	73,250	100,811	86,504
Goodwill	3,415,120	3,415,120	3,415,120
	3,488,370	3,515,931	3,501,624
Current assets
Trade and other receivables	103,615	78,643	136,785
Income tax assets	590,339	396,652	660,504
Cash and cash equivalents	1,813,718	4,302,052	3,059,001
	2,507,672	4,777,347	3,856,290
TOTAL ASSETS	5,996,042	8,293,278	7,357,914
LIABILITIES
Current liabilities	(389,101)	(509,062)	(603,912)
Trade and other payables
TOTAL LIABILITIES	(389,101)	(509,062)	(603,912)
NET CURRENT ASSETS	2,118,571	4,268,285	3,252,378
NET ASSETS	5,606,941	7,784,216	6,754,002
TOTAL EQUITY
Called up share capital	224,951	224,951	224,951
Share premium account	16,036,276	16,036,276	16,036,276
Share option reserve	641,628	569,225	613,726
Retained earnings	(11,295,914)	(9,046,236)	(10,120,951)
	5,606,941	7,784,216	6,754,002

 

 

Scancell Holdings plc

Consolidated Cash Flow Statement for the six month period to October 2015

	Unaudited Six months 31/10/2015 £	Unaudited Six months 31/10/2014 £	Unaudited Six months 30/04/2015 £
Cash flows from operating activities
Operating (loss) for the period	(1,367,775)	(1,560,813)	(2,959,995)
Depreciation	13,254	14,810	29,117
Share based payment expense	27,902	46,867	91,368
Operating (loss) profit for the year before changes in working capital	(1,326,619)	(1,499,136)	(2,839,510)
(Increase)/decrease in trade and other receivables	33,170	67,871	9,729
(Decrease)/increase in trade and other payables	(214,810)	(28,529)	66,321
Cash generated from operations	(1,508,259)	(1,459,794)	(2,763,460)
Income taxes received	250,965	124,714	124,713
Net cash from operating activities	(1,257,294)	(1,335080)	(2,638,747)
Cash flows from investing activities
Asset acquisition	-	-	-
Grant monies	9,776	5,556	64,668
Other income	2,235	49,725	49,725
Finance income	12,011	15,617	17,121
Net cash used by investing activities		70,898	131,514
Net increase/(decrease) in cash and cash equivalents	(1,245,283)	(1,264,182)	(2,507,233)
Cash and cash equivalents at beginning of the year	3,059,001	5,566,234	5,566,234
Cash and cash equivalents at end of the period	1,813,718	4,302,052	3,059,001

 

Scancell Holdings plc

Notes to the Interim Financial Statements for the period to 31 October 2015

1.Basis of preparation

This interim statement for the six month period to 31 October 2015 is unaudited and was approved by the Directors on 26 January 2016. The financial information contained in the interim report has been prepared in
accordance with the accounting policies set out in the annual report and accounts for the year ended 30 April 2015.

The financial information contained in the interim report does not constitute statutory accounts as defined in section 434 of the Companies Act 2006. The financial information for the full preceding year is based on the statutory accounts for the year ended 30 April 2015, upon which the auditors, Champion Accountants LLP, issued an unqualified audit opinion which did not contain any statement under section 498(2) or 498(3) of the
Companies Act 2006. The audited statutory accounts for the year ended 30 April 2015 have been lodged with the Registrar of Companies.

As permitted, this interim report has been prepared in accordance with AIM Rule 18 and not in accordance with IAS 34 “Interim Financial Reporting” therefore it is not fully in compliance with IFRS as adopted by the European Union.

2. Earnings per share

Basic earnings per share, from continuing operations, is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the year.
The calculations of earnings per share are based on the following losses and numbers of shares.

	Six months to 31/10/2015	Six months to 31/10/2014	Year ended 30/04/2015
Loss after taxation	(1,174,963)	(1,339,915)	(2,414,630)
Weighted average number of shares	224,950,683	224,950,683	224,950,683
Basic earnings per share	(0.52)p	(0,60)p	(1.07)p

 

       

   

At 31 October 2015 the Company had 224,950,683 Ordinary Shares of 0.1p in issue.

3. Taxation

Taxation for the six months ended 31 October 2015 is based on the effective rates of taxation which are estimated to apply for the year ended 30 April 2016.

4. Interim results

These results were approved by the Board of Directors on 26 January 2016. Copies of the interim report are available to the public from the Group’s registered office and the Group’s website, www.scancell.co.uk.

 

Scancell Holdings Plc, (AIM:SCLP), today announces the appointment of John Chiplin as Non-Executive Chairman, succeeding current Chairman David Evans who has offered his resignation to the Board in line with his personal decision to reduce his number of Non-Executive Chairman roles. John Chiplin will take on this position with immediate effect.

John Chiplin joined the Board of Scancell as a senior Non-Executive Director on 14 October 2015. John is based in the United States and his appointment as Chairman is in line with the Company’s strategy of increased focus in the US. As previously announced on 18 December 2015, the Company has formed its core US investigator team to lead a Phase 2 checkpoint inhibitor combination study with Scancell's lead cancer vaccine SCIB1.

David Evans joined the Board of Scancell as Non-Executive Chairman in 2007. During his time at the Company, David has played a key role in building Scancell into a clinical stage biotechnology company focused on the discovery and development of novel therapeutics that stimulate the immune system to treat or prevent cancer.

David Evans, outgoing Chairman, said: “I have thoroughly enjoyed my 8 years as Chairman of Scancell and I am proud of its many accomplishments. During this very productive time I have overseen the Company develop two platform technologies at the cutting edge of immuno-oncology. Scancell has also successfully progressed its lead ImmunoBody® product, SCIB1, into the clinic where it has generated compelling data that warrant its further development.

“John has a wealth of international experience in this sector, particularly in the US, and I am confident that he will successfully guide the Board and management team as the Company embarks on the next stage of development and growth.”

Dr Richard Goodfellow and Prof Durrant, joint CEOs, commented: “David’s leadership of our Board has been exemplary and his partnership and sage advice as a colleague and mentor to the management team has been invaluable. His many years of service have ensured a long and strong period of stability for Scancell, despite the challenges we have faced. His wisdom and experience have successfully guided us to the strong position we are in today, with a solid pipeline of development projects. We thank David for his contribution to Scancell and wish him well for the future.

“We are delighted that John will be taking on the role of Chairman. His significant Board experience and strong track record in the life science and technology industries makes him a clear successor and we look forward to working with him at this important time in the Company’s development.”

-ENDS-

For Further Information:

Dr Richard Goodfellow, Joint CEO	Scancell Holdings Plc	+44 (0) 20 3727 1000
Professor Lindy Durrant, Joint CEO	Scancell Holdings Plc	+44 (0) 20 3727 1000
Robert Naylor (Corporate Finance)	Panmure Gordon & Co	+44 (0) 20 7886 2714
Maisie Atkinson (Sales)	Panmure Gordon & Co	+44 (0) 20 7886 2905
Mo Noonan/Simon Conway	FTI Consulting	+44 (0) 20 3727 1000

 

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.